All In Biotech

Drug Trial Radar · NCT01274338

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,673 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,673

Actual

Start

Jun 17, 2011

Primary completion

Feb 15, 2019

Study completion Feb 2, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.

Conditions

  • Melanoma of Unknown Primary
  • Recurrent Melanoma
  • Stage IIIB Cutaneous Melanoma AJCC v7
  • Stage IIIC Cutaneous Melanoma AJCC v7
  • Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

  • IpilimumabBiological

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Recombinant Interferon Alfa-2bBiological

    Given IV and SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free Survival (RFS; Arm B [HDI] vs. Arm C [LIP])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5 and then annually up to 8 years
  2. 5-year Overall Survival (OS) Rate (Arm B [HDI] vs. Arm C [LIP])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5
  3. Recurrence-free Survival (RFS; Arm A [HIP] vs. Arm B [HDI])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5 and then annually up to 8 years
  4. 5-year Overall Survival (OS) Rate (Arm A [HIP] vs. Arm B [HDI])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5

Locations

937 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Providence Hospital

    Mobile, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Sutter Davis Hospital

    Davis, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Saint Jude Medical Center

    Fullerton, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    Los Angeles, California

  • Mattel Children's Hospital UCLA

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • Community Hospital of Monterey Peninsula

    Monterey, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

Showing 40 of 937 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.